title: Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease.
abstract: Angiotensin II (Ang II) is well-considered to be the principal effector of the renin-angiotensin system (RAS), which binds with strong affinity to the angiotensin II type 1 (AT1R) and type 2 (AT2R) receptor subtype. However, activation of both receptors is likely to stimulate different signalling mechanisms/pathways and produce distinct biological responses. The haemodynamic and non-haemodynamic effects of Ang II, including its ability to regulate blood pressure, maintain water-electrolyte balance and promote vasoconstriction and cellular growth are well-documented to be mediated primarily by the AT1R. However, its biological and functional effects mediated through the AT2R subtype are still poorly understood. Recent studies have emphasized that activation of the AT2R regulates tissue and organ development and provides in certain context a potential counter-regulatory mechanism against AT1R-mediated actions. Thus, this review will focus on providing insights into the biological role of the AT2R, in particular its actions within the renal and cardiovascular system.
authors.affiliation: JDRF Danielle Alberti Memorial Centre for Diabetic Complications, Diabetic Complications Division, Baker IDI Heart and diethyl Research Institute, Melbourne, VIC 3004, Australia.
authors.forename: Bryna S M
authors.initials: BS
authors.lastname: Chow
authors.affiliation: JDRF Danielle Alberti Memorial Centre for Diabetic Complications, Diabetic Complications Division, Baker IDI Heart and diethyl Research Institute, Melbourne, VIC 3004, Australia Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, VIC 3004, Australia terri.allen@bakeridi.edu.au.
authors.forename: Terri J
authors.initials: TJ
authors.lastname: Allen
mesh_terms: D000804:Angiotensin II / Q000378:metabolism*; D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D002319:Cardiovascular System / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D044139:Receptor, Angiotensin, Type 2 / Q000819:agonists / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000187:drug effects; D015398:Signal Transduction
chemical_list: C544065:AGTR1 protein, human; D002317:Cardiovascular Agents; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D000804:Angiotensin II
keywords: AT2 receptor; AT2R agonism; cardiovascular; compound 21; kidney